Pharvaris Presents on safety of combining deucrictibant XR and IR at CIIC

Pharvaris presented data evaluating safety margins of combining deucrictibant immediate-release (IR) with deucrictibant extended-release (XR) tablet at the Consortium of Independent Immunology Clinics (CIIC) conference, held 17-19 April. The results demonstrated that combined use of a 40 mg deucrictibant XR tablet for prophylaxis and 1 or 2 deucrictibant IR 20 mg capsule(s) in the event of a breakthrough attack, while on prophylaxis, is supported by evidence of adequate safety margins. This builds on previously reported post-hoc analysis which showed that using icatibant (B2R antagonist, injectable) in the rescue setting while patients are on deucrictibant for prophylaxis led to comparable efficacy. We view this as a potential differentiator for Pharvaris, where having both an on-demand and a prophylactic option creates cross-selling opportunities, which we expect to support commercial uptake. $36 TP and Buy maintained.